Lexicon Pharmaceuticals to Present Sotagliflozin Clinical Data at the European Association for the Study of Diabetes 55th Ann...
September 10 2019 - 4:01PM
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today announced that
clinical data for ZynquistaTM (sotagliflozin) will be presented at
the upcoming European Association for the Study of Diabetes (EASD)
55th annual meeting (September 16-20; Barcelona, Spain). The
accepted abstracts, including two oral presentations, reflect
Lexicon’s efforts to address the unmet need for new options for the
management of type 1 diabetes.
Oral Presentations (all times
local)
- Tuesday, September 17, 10:15 am-11:45 am; Session OP 01: “SGLT2
Inhibitors: Glucose and Beyond”; Joslin Hall
- “Sotagliflozin, a Dual SGLT1 and
SGLT2 Inhibitor, in Overweight/Obese Patients with Type 1 Diabetes:
Addressing Unmet Needs as Adjunct Therapy to Insulin” (Abstract
#2)
- “Effect of Sotagliflozin on Body
Weight and Composition in Adults with Type 1 Diabetes” (Abstract
#3)
Posters
- Wednesday, September 18, 12:00 pm-1:00 pm; Session PS 051:
“SGLT2 Inhibitors in Type 1 Diabetes: Benefits and Harms”; Poster
Hall
- “Sotagliflozin Reduces Glucose
Variability and Risk for Hyperglycemia in Adults with Type 1
Diabetes” (Abstract #717)
- “Improved Treatment Satisfaction in
Patients with Type 1 Diabetes Treated with Sotagliflozin Plus
Insulin vs. Insulin Alone” (Abstract #724)
- Wednesday, September 18, 12:00
pm-1:00 pm; Session PS 065: “Clinical Aspects of Hypoglycemia”;
Poster Hall
- “Sotagliflozin Leads to Lower Rates of Clinically Relevant
Hypoglycemic Events at Any HbA1c Level at Week 52 in Adults with
Type 1 Diabetes” (Abstract #849)
- Wednesday, September 18, 1:15
pm-2:15 pm; Session PS 082: “Promising Therapeutic Options for
Diabetic Kidney Disease”; Poster Hall
- “The Impact of Sotagliflozin on Renal Function, Albuminuria and
Blood Pressure in Adults with Type 1 Diabetes” (Abstract
#1000)
- Wednesday, September 18, 1:15 pm-2:15 pm; Session PS 100:
Treatment of Cardiovascular Disease"; Poster Hall
- “Sotagliflozin Reduces Markers of
Arterial Stiffness in Type 1 Diabetes: Pooled Analysis from
inTandem1 and inTandem2 Clinical Trials” (Abstract #1166)
About Zynquista
(sotagliflozin)
Discovered using Lexicon’s unique approach to
gene science, Zynquista is an oral dual inhibitor of two proteins
responsible for glucose regulation known as sodium-glucose
co-transporter types 1 and 2 (SGLT1 and SGLT2). SGLT1 is
responsible for glucose absorption in the gastrointestinal tract,
and SGLT2 is responsible for glucose reabsorption by the kidney.
Zynquista is approved in the European Union (EU) for use as an
adjunct to insulin therapy to improve blood sugar (glycemic)
control in adults with type 1 diabetes with a body mass index ≥ 27
kg/m2, who could not achieve adequate glycemic control despite
optimal insulin therapy. Outside of such approval, Zynquista is
investigational and has not been approved by any other regulatory
authority for type 1 or type 2 diabetes.
About Lexicon
Pharmaceuticals
Lexicon is a fully integrated biopharmaceutical
company with a mission of pioneering medicines that transform
patients’ lives. Through its Genome5000™ program, Lexicon
scientists studied the role and function of nearly 5,000 genes and
identified more than 100 protein targets with significant
therapeutic potential in a range of diseases. Through the precise
targeting of these proteins, Lexicon is pioneering the discovery
and development of innovative medicines to safely and effectively
treat disease. In addition to its first commercial product,
XERMELO, Lexicon has a pipeline of promising drug candidates in
clinical and preclinical development in diabetes and metabolism,
oncology and neuropathic pain. For additional information, please
visit www.lexpharma.com.
Safe Harbor Statement
This press release contains “forward-looking
statements,” including statements relating to Lexicon’s long-term
outlook on its business, the commercialization of XERMELO
(telotristat ethyl) and Zynquista (sotagliflozin), and the clinical
development of, the regulatory filings for, and the potential
therapeutic and commercial potential of telotristat ethyl,
sotagliflozin, LX2761 and LX9211. In addition, this press release
also contains forward looking statements relating to Lexicon’s
growth and future operating results, discovery, development and
commercialization of products, strategic alliances and intellectual
property, as well as other matters that are not historical facts or
information. All forward-looking statements are based on
management’s current assumptions and expectations and involve
risks, uncertainties and other important factors, specifically
including Lexicon’s ability to meet its capital requirements,
successfully commercialize XERMELO, successfully conduct
preclinical and clinical development and obtain necessary
regulatory approvals of telotristat ethyl, sotagliflozin, LX2761,
LX9211 and its other potential drug candidates on its anticipated
timelines, achieve its operational objectives, obtain patent
protection for its discoveries and establish strategic alliances,
as well as additional factors relating to manufacturing,
intellectual property rights, and the therapeutic or commercial
value of its drug candidates. Any of these risks, uncertainties and
other factors may cause Lexicon’s actual results to be materially
different from any future results expressed or implied by such
forward-looking statements. Information identifying such important
factors is contained under “Risk Factors” in Lexicon’s annual
report on Form 10-K for the year ended December 31, 2018, as filed
with the Securities and Exchange Commission. Lexicon undertakes no
obligation to update or revise any such forward-looking statements,
whether as a result of new information, future events or
otherwise.
For Investor Inquiries:
Kimberly Lee, D.O.Head of Investor Relations and
Corporate StrategyLexicon Pharmaceuticals(281)
863-3383klee@lexpharma.com
For Media Inquiries:
Chas SchultzExecutive Director, Corporate
Communications and Patient AdvocacyLexicon Pharmaceuticals(281)
863-3421cschultz@lexpharma.com
Lexicon Pharmaceuticals (NASDAQ:LXRX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Lexicon Pharmaceuticals (NASDAQ:LXRX)
Historical Stock Chart
From Jul 2023 to Jul 2024